Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Fiercebiotech

Published November 16, 2026 · Updated November 17, 2026

Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech

Read the full story at Fiercebiotech

The company, a 2025 inductee into Fierce Biotech's Fierce ... Helus' chemically modified psychedelic hits key goals in phase 3 depression trial.

Surfaced by this Google Alert

  • Psychedelic biotech